Drugs / JNJ-67484703
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04985812 | Oct 2021 → May 2023 | rheumatoid arthritis | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-67484703 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04985812 ↗ |
| Action | Activate | “JNJ-67484703 is a humanized antibody designed to target and activate PD-1 and restore normal immune function.” PMID 41146691 ↗ Oct 2025 |
| Modality | Monoclonal antibody | “JNJ-67484703 is a humanized IgG anti-PD-1 agonist antibody.” PMID 41146691 ↗ Oct 2025 |
| Route | Subcutaneous | “JNJ-67484703 at doses of 2 or 3 mg/kg or placebo was administered by subcutaneous injection for 10 weeks” PMID 41146691 ↗ Oct 2025 |